Fianostics GmbH

FIANOSTICS develops highly sensitive fluorescence immunoassays and a new metal enhanced fluorescence platform in cooperation with SonyDADC BioSciences. The medical focus of FIANOSTICS will initially be placed on diseases of bone and cartilage followed by neurological disorders, because clinical research in those areas, which become more and more important due to the ongoing demographic changes, will significantly benefit from high sensitivity Biomarker tests.